ArticleBrain research2015
P50: A candidate ERP biomarker of prodromal Alzheimer's disease.
Article in Brain research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03644043 (Quantitative EEG for Assessment of Mild Cognitive Impairment Associated With Preclinical Alzheimer's Disease - Evidence for Amyloid Indication Study), which is not on this map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Quantitative EEG for Assessment of Mild Cognitive Impairment Associated With Preclinical Alzheimer's Disease - Evidence for Amyloid Indication Study
Who cites it
7 citing papers in PubMed, 32 citations in OpenAlex.
- Neural features underlying high-accuracy classification of amnestic mild cognitive impairment using multi-sensory-evoked potentials.GeroScience · 2026Article
- Relationship between executive function and activities of daily living in Alzheimer's disease: a study based on the stop-signal task.Frontiers in aging neuroscience · 2026Article
- The Use of Event Related Potentials to Predict Amyloid PET Status Among Patients from a Memory Disorders Clinic.Journal of Alzheimer's disease : JAD · 2024Article
- Potential Role of OERP as Early Marker of Mild Cognitive Impairment.Frontiers in aging neuroscience · 2018Article
- MEG biomarker of Alzheimer's disease: Absence of a prefrontal generator during auditory sensory gating.Human brain mapping · 2017Article
- Prevention of Alzheimer's Disease: Lessons Learned and Applied.Journal of the American Geriatrics Society · 2017Article
- Future perspectives toward the early definition of a multivariate decision-support scheme employed in clinical decision making for senior citizens.Healthcare technology letters · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
introductionReductions of cerebrospinal fluid (CSF) amyloid-beta (Aβ42) and elevated phosphorylated-tau (p-Tau) reflect in vivo Alzheimer's disease (AD) pathology and show utility in predicting conversion from mild cognitive impairment (MCI) to dementia. We investigated the P50 event-related potential component as a noninvasive biomarker of AD pathology in non-demented elderly.
methods36 MCI patients were stratified into amyloid positive (MCI-AD, n=17) and negative (MCI-Other, n=19) groups using CSF levels of Aβ42. All amyloid positive patients were also p-Tau positive. P50s were elicited with an auditory oddball paradigm.
resultsMCI-AD patients yielded larger P50s than MCI-Other. The best amyloid-status predictor model showed 94.7% sensitivity, 94.1% specificity and 94.4% total accuracy. DISCUSSION: P50 predicted amyloid status in MCI patients, thereby showing a relationship with AD pathology versus MCI from another etiology. The P50 may have clinical utility for inexpensive pre-screening and assessment of Alzheimer's pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.